Received Oct 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLULAVAL) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Possible given SQ instead of IM; This non-serious case was reported by a nurse via sales rep and described the occurrence of intramuscular formulation administered by other route in a patient who received Flu Seasonal TIV Quebec (FluLaval 2025-2026 season) for prophylaxis. On 09-OCT-2025, the patient received the 1st dose of FluLaval 2025-2026 season. On 09-OCT-2025, an unknown time after receiving FluLaval 2025-2026 season, the patient experienced intramuscular formulation administered by other route (Verbatim: Possible given SQ instead of IM). The outcome of the intramuscular formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 09-OCT-2025 The nurse called to understand if they needed to readminister Flulaval to 60 employees since a 5/8 inch needle was provided for administration instead of a 1 inch needle. She was unsure how many employees may need to be revaccinated due to their size and the needle side used. Possibly Flulaval given subcutaneous instead of intramuscular route.